

Estimates of TB burden <sup>o</sup> , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	0.48 (0.37–0.61)	54 (42–69)
HIV-positive TB incidence	0.025 (0.014–0.04)	2.9 (1.6–4.5)
MDR/RR-TB incidence <sup>oo</sup>	<0.01 (<0.01–<0.01)	0.35 (0.2–0.54)
HIV-negative TB mortality	0.038 (0.037–0.038)	4.2 (4.2–4.3)
HIV-positive TB mortality	<0.01 (<0.01–<0.01)	0.6 (0.31–0.97)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	0.68%
Previously treated cases	0% (0–34)

TB case notifications, 2018

Total new and relapse	385
- % tested with rapid diagnostics at time of diagnosis	95%
- % with known HIV status	89%
- % pulmonary	68%
- % bacteriologically confirmed <sup>ooo</sup>	55%
- % children aged 0-14 years	20%
- % women	34%
- % men	46%
Total cases notified	389

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	80% (63–100)
TB patients facing catastrophic total costs, 2017	40% (33–47)
TB case fatality ratio (estimated mortality/estimated incidence), 2018	9% (7–11)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	18	5%
- on antiretroviral therapy	17	94%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance <sup>ooo</sup>	
- New cases	110%
- Previously treated cases	100%
Laboratory-confirmed cases*	MDR/RR-TB: 1, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 1, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	0

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	81%	352
Previously treated cases, excluding relapse, registered in 2017	86%	7
HIV-positive TB cases registered in 2017	89%	9
MDR/RR-TB cases started on second-line treatment in 2016	100%	1
XDR-TB cases started on second-line treatment in 2016		0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100%

TB financing, 2019

National TB budget (US\$ millions)	1.3
Funding source: 80% domestic, 2% international, 19% unfunded	

<sup>o</sup> Ranges represent uncertainty intervals

<sup>oo</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


<sup>ooo</sup> Calculated for pulmonary cases only

\* Includes cases with unknown previous TB treatment history

\*\* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




Legend:  
■ Total TB incidence  
■ New and relapse TB cases notified  
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:  
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:  
■ Females ■ Males  Incidence

Treatment success rate (%)



Legend:  
■ New and relapse  
■ Retreatment, excluding relapse  
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:  
■ Unfunded  
■ Funded internationally  
■ Funded domestically